VIVOS THERAPEUTICS INC (VVOS) Forecast, Price Target & Analyst Ratings

NASDAQ:VVOS • US92859E2072

1.24 USD

-0.06 (-4.62%)

Last: Mar 13, 2026, 08:02 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VIVOS THERAPEUTICS INC (VVOS).

Consensus Price Target

Price Target

$5.10

+ 311.29% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: Mar 30, 2026
Period: Q4 / 2025
EPS Estimate: -$0.49
Revenue Estimate: 6.576M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

80.00%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$5.10

Upside

+ 311.29%

From current price of $1.24 to mean target of $5.10, Based on 9 analyst forecasts

Low

$2.53

Median

$5.61

High

$7.35

Price Target Revisions

1 Month

0.00%

3 Months

-9.09%

Price Target Summary

9 Wall Street analysts provided a forecast for the next 12 months for VVOS. The average price target is 5.1 USD. This implies a price increase of 311.29% is expected in the next year compared to the current price of 1.24.

The average price target has been revised downward by 9.09% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

80.00%

VVOS was analyzed by 9 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about VVOS.

In the previous month the buy percentage consensus was at a similar level.

VVOS was analyzed by 9 analysts. More opinions would make the average more meaningful.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2025-12-03	Ascendiant Capital	Maintains	Buy -> Buy
2025-11-17	HC Wainwright & Co.	Initiate	Buy
2025-09-09	Ascendiant Capital	Maintains	Buy -> Buy
2025-04-15	Ascendiant Capital	Maintains	Buy -> Buy
2024-11-20	Ascendiant Capital	Reiterate	Buy -> Buy
2024-11-19	Alliance Global Partners	Maintains	Buy -> Buy
2024-08-20	Ascendiant Capital	Maintains	Buy -> Buy
2023-01-17	Ascendiant Capital	Initiate	Buy
2021-08-13	Roth Capital	Maintains	Buy
2021-05-18	Roth Capital	Maintains	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: Mar 30, 2026
Period: Q4 / 2025
EPS Estimate: -$0.49
Revenue Estimate: 6.576M
Revenue Q2Q: 77.83%
EPS Q2Q: -76.07%
Number of Analysts: 5

Next Earnings Revisions

Revenue (1 Month)

2.38%

Revenue (3 Months)

15.17%

EPS (1 Month)

0.00%

EPS (3 Months)

-8.21%

Next Earnings Summary

VVOS is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.49 USD and the consensus revenue estimate is 6.58M USD.

The next earnings revenue estimate has been revised upward by 15.17% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2022	2023	2024	2025	2026
Revenue YoY % growth	16.02M -5.15%	13.801M -13.85%	15.031M 8.91%	19.753M 31.42%	29.593M 49.82%
EBITDA YoY % growth	-24.36M -29.99%	-16.675M 31.55%	-10.59M 36.49%	-17.932M -69.33%	-13.726M 23.45%
EBIT YoY % growth	-25.03M -28.56%	-17.296M 30.90%	-11.171M 35.41%	-17.815M -59.48%	-15.301M 14.11%
Operating Margin	-156.24%	-125.32%	-74.32%	-90.19%	-51.71%
EPS YoY % growth	-20.08 18.04%	-10.92 45.62%	-2.91 73.35%	-2.07 28.96%	-1.28 38.32%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q4 / 25	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	-0.49 -76.07%	-0.42 5.93%	-0.38 30.45%	-0.36 27.14%	-0.33 32.76%
Revenue Q2Q % growth	6.576M 77.83%	6.375M 111.37%	6.783M 77.57%	7.14M 5.26%	6.63M 0.82%
EBITDA Q2Q % growth	-4.595M -106.52%	-4.59M -22.69%	-4.284M 2.24%	-4.182M -8.15%	-1.53M 66.70%
EBIT Q2Q % growth	-4.812M -71.50%	-4.59M -17.15%	-4.284M 11.94%	-4.182M 11.66%	-1.53M 68.21%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

N/A

EPS Next 5 Year

N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

VIVOS THERAPEUTICS INC / VVOS Forecast FAQ

What is the average price target for VIVOS THERAPEUTICS INC (VVOS) stock?

9 analysts have analysed VVOS and the average price target is 5.1 USD. This implies a price increase of 311.29% is expected in the next year compared to the current price of 1.24.

Can you provide the upcoming earnings date for VIVOS THERAPEUTICS INC?

VIVOS THERAPEUTICS INC (VVOS) will report earnings on 2026-03-30, after the market close.

What are the consensus estimates for VIVOS THERAPEUTICS INC (VVOS) next earnings?

The consensus EPS estimate for the next earnings of VIVOS THERAPEUTICS INC (VVOS) is -0.49 USD and the consensus revenue estimate is 6.58M USD.

Analyst forecast overview

Forecast Snapshot